Serlopitant shows promise for psoriatic pruritus in phase 2 trial

  • Pariser DM & al.
  • J Am Acad Dermatol
  • 30 Jan 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Serlopitant, a neurokinin 1 receptor antagonist, is associated with improved itch symptoms in patients with psoriatic pruritus, according to a phase 2 clinical trial.

Why this matters

  • Many available treatment options for psoriasis do not adequately address pruritus.

Key results

  • Vs placebo, serlopitant was associated with a higher worst itch numeric rating scale (WI-NRS) response rate at:
    • 4 weeks: 20.8% vs 11.5% (P=.039). 
    • 8 weeks: 33.3% vs 21.1% (P=.028).
  • 4.9% of patients who received serlopitant and 4.0% of patients who received placebo experienced treatment-related adverse events.

Study design

  • 204 patients with psoriatic pruritus were randomly assigned to serlopitant 5 mg or placebo daily for 8 weeks.
  • Funding: Menlo Therapeutics, Inc.

Limitations

  • Relatively small patient sample size.
  • Short trial duration.
  • Patients with severe psoriasis were excluded.